Christopher Ocampo
Head of Psychiatry, Neuroscience Clinical Development Abbvie
Seminars
Wednesday 16th September 2026
Panel Discussion: Overcoming the Phase 2/3 Roadblock in Neuropsychiatric Drug Development: What Have We Learnt in 2026?
8:00 am
- What recent Phase 2 and Phase 3 readouts have taught us about target validation in neuropsychiatric drug development?
- How can sponsors better address persistent challenges around placebo response, site quality and trial execution?
- To what extent do indication selection and patient population definitions influence the probability of success?
- How can biomarkers, precision psychiatry approaches and improved patient stratification help derisk future development programmes?
- What lessons from recent successes and setbacks should shape the next generation of neuropsychiatric clinical trials?
Wednesday 16th September 2026
Panel Discussion: Neuropsychiatry at a Crossroads: Where Science, Strategy & Deal Making Converge
9:00 am
- What are the key neuropsychiatry priorities currently shaping strategy at Lilly, AbbVie and Lundbeck?
- To what extent is business development becoming a critical lever for growth and portfolio expansion?
- Which mechanisms, symptoms and indications are generating the greatest excitement and investment across the field?
- What does the future of psychiatry look like, and where will the next wave of innovation come from?
